Results vary, but many clients start noticing changes in their eating habits within a few weeks
GLP-1 pentareceptor agonist From September 15 to 19, 2025, the 61st annual meeting of the European Association for diabetes Research (EASD) was held in Vienna
At 24 weeks, average weight loss was: At 48 weeks, average weight loss was: The study also found that, at 48 weeks, 100% of people taking 12mg lost at least 5% of their body weight , 93% lost at least 10% , and 83% lost at least 15%
This explains the clinical data
The physiology of glucagonlike peptide 1
As more evidence becomes available on the GLP-1s, expect the halo impact on overlapping comorbidities to accelerate their adoption